



Inhibition of Metastasis by Polypyridyl Ru(II) Complexes through Modification of Cancer Cell Adhesion – In Vitro Functional and Molecular Studies

Ilona Gurgul, Ewelina Janczy-Cempa, Olga Mazuryk, Malgorzata Lekka, Michal Łomzik, Franck Suzenet, Philippe Gros, Malgorzata Brindell

► To cite this version:

Ilona Gurgul, Ewelina Janczy-Cempa, Olga Mazuryk, Malgorzata Lekka, Michal Łomzik, et al.. Inhibition of Metastasis by Polypyridyl Ru(II) Complexes through Modification of Cancer Cell Adhesion – In Vitro Functional and Molecular Studies. *Journal of Medicinal Chemistry*, 2022, 65 (15), pp.10459-10470. <10.1021/acs.jmedchem.2c00580>. <hal-03764282>

HAL Id: hal-03764282

<https://hal.science/hal-03764282v1>

Submitted on 24 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Inhibition of metastasis by polypyridyl Ru(II) complexes through modification of cancer cell adhesion – *in vitro* functional and molecular studies

Ilona Gurgul^{#,1}, Ewelina Janczy-Cempa^{#,1}, Olga Mazuryk^{*,1}, Małgorzata Lekka², Michał Łomzik^{3,1}, Franck Suzenet⁴, Philippe C. Gros⁵, Małgorzata Brindell^{*,1}

¹*Faculty of Chemistry, Jagiellonian University in Krakow, Gronostajowa 2, 30-387 Krakow, Poland;*

²*Department of Biophysical Microstructures, Institute of Nuclear Physics, Polish Academy of Sciences, PL-31342 Krakow, Poland*

³*Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, ul. Tamka 12, 91-403 Łódź, Poland*

⁴*Institute of Organic and Analytical Chemistry, University of Orléans, UMR-CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans Cedex 2, France*

⁵*Université de Lorraine, CNRS, L2CM, F-54000 Nancy, France*

Abstract

The effect of polypyridyl Ru(II) complexes on the ability of cancer cells to migrate and invade, two features important in the formation of metastases, is evaluated. *In vitro* studies are carried out on breast cancer cell lines, MDA-MB-231 and MCF-7, as well as melanoma cell lines A2058 and A375. Three Ru(II) complexes comprising two 4,7-diphenyl-1,10-phenanthroline (dip) ligands while the third ligand is 2,2'-bipyridyne (bpy) or its derivative with either a 4-[3-(2-nitro-1H-imidazol-1-yl)propyl] (bpy-NitroIm) or 5-(4-{4'-methyl-[2,2'-bipyridine]-4-yl}but-1-yn-1-yl)pyridine-2-carbaldehyde semicarbazone (bpy-SC) moiety attached are examined. The low sub-toxic doses of the studied compounds greatly affected

cancer cells by inhibiting cell detachment, migration, invasion, transmigration, and re-adhesion, as well as increasing cell elasticity. The molecular studies revealed that Ru(II) polypyridyl complexes impact the activity of the selected integrins and upregulate the expression of focal adhesion components such as vinculin and paxillin leading to an increased number of focal adhesion contacts.

Keywords

ruthenium complexes, cytotoxicity, uptake, cell adhesion properties, melanoma cells, breast cancer cells, cell migration, cell invasion, integrins, focal adhesion, cell elasticity

1. Introduction

Undoubtedly, chemotherapy is a powerful weapon in the fight against cancer. Despite the increasing amount of data on the effects of chemotherapeutic agents, which were drawn not only from *in vivo* research but also from clinical trials and therapy, there are still some problems to be solved. An important question that researchers have recently raised is the link between chemotherapy and the promotion of cancer metastasis.¹ However, this topic is little investigated and there are only a few reports that address this problem in *in vivo* or clinical studies. For example, *in vivo* studies on human breast xenograft models in mice showed that basic anticancer drugs in the adjuvant and neoadjuvant treatment of cancer can promote the formation of distant metastases through increased intravasation.² The clinical results addressed to this issue are not clear.³ There is no direct evidence (data) that pro-metastatic changes in ER+ breast cancers result from the use of neoadjuvant chemotherapy.⁴ Importantly, a benefit in the application of neoadjuvant chemotherapy manifested in improved survival in complete pathological response was evident. Therefore, one must be very careful in formulating conclusions from these studies and this issue requires further extensive


research and clarification. Other clinical studies revealed the negative impact of tamoxifen on disease-free survival and metastasis-free survival of patients with ER α 36+ breast cancer treated with this drug after surgery.⁵ It was proposed that tamoxifen interacts directly with ER α 36+ expressed by breast cancer cells, which in turn induces proliferation and metastasis of breast cancer. Generally, clinical studies are very challenging because they deal with a heterogeneous group of patients with diverse prognoses; therefore, large-scale studies considering various parameters are needed to establish if there is indeed a link between systemic therapies and metastasis. However, in recent years, there have been voices from oncologists and scientists that research on new drugs should also include studies to determine whether chemotherapy can promote metastases.⁶

Achieving of the cytotoxic concentration of drugs reaching cancer cells is often prevented by their poor biodistribution resulting from deprived tumor vascularization and the occurrence of hypoxia. Therefore, typically maximum tolerated doses (MTD) are applied in the treatment, which leads to host toxicity and diverse side effects. However, recently low-dose metronomic chemotherapy (LDM) was suggested as an alternative form of chemotherapy, particularly for those patients who may not be considered for MTD due to poor health conditions.⁷ In LDM chemotherapy, low doses of drugs are administered on a frequent or continuous schedule without extended interruptions. Although there are only a few available studies, some observations indicated that LDM chemotherapy might induce less metastasis-favorable changes in the tumor microenvironment than standard chemotherapy.^{1b} Clinical trials on the evaluation of “*Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer*” (ClinicalTrials.gov Identifier: NCT04350021) are currently in progress. Therefore, for any new potential cytotoxic agent, it is important to know how non-toxic doses affect cancer cells, and whether they can have any beneficial effects or on the contrary may increase the risk of developing distant metastasis.


Among the compounds tested as antimetastatic drugs, one of the ruthenium complexes, namely imidazolium *trans*-[tetrachlorido(1H-imidazole)(S-dimethylsulphoxide)ruthenate(III)] known as NAMI-A and its sodium salt precursor, (NAMI), deserved attention of researchers.⁸ NAMI-A was the first and only metal complex that entered the clinical trials as a nontoxic compound exhibiting antimetastatic properties in animal models. Their unique features arise from inhibiting the main stages of the dissemination process.^{8c} Among others, it significantly increased the adhesion strength of cells and reduced the rates of invasion and transmigration through endothelial cells. Furthermore, it inhibited the secretion of proteolytic enzymes such as MMP-2 and MMP-9, which play a significant role in cancer cell survival and expansion since they are involved in all stages of carcinogenesis. It modulated the tumor microenvironment by changing the activity and/or expression of various adhesion molecules and integrins. Despite the failure of the clinical investigation, the research on NAMI-A development by Enzo Alessio, Gianni Sava, and Giovanni Mestroni became a milestone in the field of anticancer metal compounds directing the attention of researchers to antimetastatic studies. Another group of compounds that exerted antimetastatic activity with low cytotoxic activity was a series of organometallic ruthenium(II)-arene complexes developed by Paul Dyson. RAPTA-C, [Ru(p-cymene)Cl₂(PTA)] (PTA - 1,3,5-triaza-7-phosphaadamantane), has been particularly well studied, and its antimetastatic activity was assigned to its binding to the histone proteins in nucleosome core particles by alternating chromatin compaction.⁹ Research has recently commenced on Ru polypyridyl complexes to test their potential to inhibit metastasis development, with promising results.¹⁰


In this work, we address the issues mentioned above by examining the effect of the tested compounds in low sub-toxic doses on the properties of cancer cells, which are important for their ability to metastasize. Our previous studies on human lung adenocarcinoma A549 and human pancreatic carcinoma PANC-1 showed that **Ru1** and **Ru3** (the structure are depicted in


Figure 1) substantially decreased cells' susceptibility to detachment when cultured either on plastic or collagen-coated surfaces. On the other hand, cells pre-treated with the same Ru(II) complexes exhibited a lower ability to re-adhere to a substrate after detachment.¹¹ A similar effect on breast cancer 4T1 cell adhesion was observed after **Ru2** treatment (the structure is depicted in **Figure 1**).¹² Cell adhesion is a functional characteristic of cells that plays a crucial role in cancer progression and metastasis. Furthermore, we have shown that **Ru3** inhibited the released and membrane-bound metalloproteinases (MMPs) in A549 cells, while in model studies, both **Ru1** and **Ru3** directly inhibited MMP-2 and MMP-9 enzyme activities.¹³ Such preliminary findings encouraged us to select these complexes (**Ru1-Ru3**, see **Figure 1**) as good candidate compounds for testing of their potency in the inhibition of metastasis by influencing cell detachment, migration, invasion, transmigration, re-adhesion, as well as their elasticity. For *in vitro* studies, two breast cancer cell lines, MDA-MB-231 and MCF-7, and two melanoma cell lines, A2058 and A375, were chosen. MDA-MB-231, the triple-negative breast adenocarcinoma cell line, is highly invasive, aggressive, and poorly differentiated. These properties are due to the lack of expression of estrogen (ER) and progesterone (PR) receptors, as well as human epidermal growth factor receptor (HER2).¹⁴ The invasion of MDA-MB-231 cells was related to their ability for proteolytic degradation of the extracellular matrix (ECM). MCF-7 is an estrogen-responsive (ER-positive and PR-positive) breast adenocarcinoma cell line, which is generally considered to have low metastatic potential.¹⁵ A2058 is a highly invasive melanoma cell line characterized by high collagen type IV collagenase expression and low endogenous expression of Wnt5a. High levels of α_v integrin expression, tissue inhibitor of metalloproteinase-2, and autocrine motility factor are responsible for its high metastatic potential.¹⁶ A375 is a human malignant melanoma cell line with low metastatic potency, characterized by the presence of adenosine receptors, responsible for modulating tumor processes.¹⁷ Studies for the melanoma cells were also



$[Ru(dip)_2(bpy)]Cl_2$ (**Ru1**): R1=H, R2=H

$[Ru(dip)_2(bpy-Nitrolm)]Cl_2$ (**Ru2**): R1=H R2= 

$[Ru(dip)_2(bpy-SC)]Cl_2$ (**Ru3**): R1= CH₃ R2= 



was much higher than that of the well-known cisplatin. An especially promising property is their particular cytotoxicity against triple-negative breast cancer MDA-MB-231 cells, since cisplatin treatment of triple-negative breast cancer often results in the development of chemoresistance.¹⁹ Application of all compounds to cells grown under hypoxic conditions resulted in a decrease in their cytotoxic efficacy. Notably, for all three Ru complexes, the cytotoxicity against the human non-tumor HaCat cells was lower compared to that against cancer cells. At the same time, cisplatin remained at the same level. Among others, Ru complexes were 5-20 times less cytotoxic against HaCat than against MDA-MB-231 cells.

Table 1. Cytotoxicity (IC₅₀) of Ru(II) complexes and cisplatin evaluated for A375, A2058, MCF-7, MDA-MB-231, and HaCat cells under normoxia (21% O₂) and hypoxia (1% O₂) conditions.

Cell line (conditions)	IC ₅₀ /μM			
	Ru1	Ru2	Ru3	cisplatin
A375 (normoxia)	9.7 ± 0.4	11.2 ± 0.9	15.0 ± 0.6	61 ± 5
A375 (hypoxia)	8.4 ± 0.2	20 ± 1	12 ± 2	145 ± 30
A2058 (normoxia)	4.9 ± 0.9	10.8 ± 0.8	4.7 ± 0.5	53 ± 9
A2058 (hypoxia)	6.7 ± 0.3	18 ± 3	15 ± 2	182 ± 44
MCF-7 (normoxia)	3.9 ± 0.6	13 ± 2	13.1 ± 0.3	54 ± 6
MDA-MB-231 (normoxia)	0.8 ± 0.6	3.8 ± 0.2	1.8 ± 0.3	82 ± 3
HaCat (normoxia)	22 ± 3	19 ± 4	27.7 ± 0.8	71 ± 14
HaCat (hypoxia)	14 ± 3	16 ± 2	18.6 ± 0.6	41 ± 2

The accumulation of Ru ions in various cell lines was studied for all tested compounds at concentrations of 1/8 IC₅₀, and 1/4 IC₅₀ to check the amount of individual compounds

needed to exert the same biological effect. The amount of Ru ions accumulated in cells evaluated by ICP-MS together with the concentrations used for incubation are shown in **Fig. 2**. The three compounds accumulated readily in each type of used cells, as clearly revealed by an increase in the concentration of ruthenium accumulated in cells in relation to the concentration in the cell medium, 20 to even 120 times. Cellular uptake of complexes was dose-dependent and strongly dependent on the cell line (**Fig. 2**). Interestingly, the highest cytotoxicity to MDA-MB-231 cells was not due to the high accumulation of compounds, but rather to the susceptibility of the cells to their activity. MCF-7 cells remained the most resistant, especially to **Ru3**, requiring a very high concentration in the cell of ca. 450 μM to obtain $1/4 \text{ IC}_{50}$, while for other cell lines it was below 120 μM . The propensity to accumulate in cells is an important factor in cytotoxic activity, but the ability to reach and interact with the appropriate targets in the cell plays a key role.




Fig. 2. Ruthenium accumulation in **A) A375**, **B) A2058**, **C) MCF-7** and **D) MDA-MB-231** determined after 24 h of incubation with **[Ru(dip)₂(bpy)]Cl₂ (Ru1, blue)**, **[Ru(dip)₂(bpy-NitroIm)]Cl₂ (Ru2, gray)** and **[Ru(dip)₂(bpy-SC)]Cl₂ (Ru3, red)** presented as concentration in a single cell (obtained from ICP-MS measurements). Concentrations for individual Ru(II) compounds applied as 1/4 or 1/8 of IC₅₀ are given above each bar.

2.2. Impact on cancer cells adhesion and re-adhesion properties

The potential of Ru(II) compounds to increase cell adhesion properties was verified by applying the trypsin resistance assay.²⁰ Cells, 24 h after the treatment with the tested compounds, were exposed to a diluted trypsin solution for a short time to minimize cell disruption, and the amount of remaining trypsin-resistant cells was quantified using a resazurin assay. The studies were carried out on cells with different invasiveness potentials and the obtained results indicated that the treatment of highly metastatic A2058 cells with Ru(II) compounds had a rather low effect on their adherence to plastic under both normoxic and hypoxic conditions (**Fig. 3**). On the other hand, cells from the other lines exhibited even a doubled adherence under normoxic conditions (**Fig. 3**). Treatment of highly metastatic MDA-MB-231 cells with **Ru3** resulted in a pronounced reinforcement of cell adhesion. The increase in the concentration of compounds from 1/8 of IC₅₀ to 1/4 of IC₅₀ had no evident impact on the observed effects (**Fig. S1**). However, a decreased effect on adhesion was noted for A375 cells growth under hypoxia. Therefore, the observed effect strongly depends on the type of cell line, pointing to a large heterogeneity between cancer cells.




Fig. 3. Cell adhesion was evaluated as a percentage of adherent cells that remained after controlled trypsin treatment. Cells were incubated with **[Ru(dip)₂(bpy)]Cl₂ (Ru1, blue)**, **[Ru(dip)₂(bpy-NitroIm)]Cl₂ (Ru2, grey)** and **[Ru(dip)₂(bpy-SC)]Cl₂ (Ru3, red)** at a concentration equal to 1/8 of IC₅₀ under normoxic (filled bar) and hypoxic (dashed bar) conditions. Untreated cells were used as a control (100%, dashed line). *p<0.05

In addition, the re-adhesion of cells treated with Ru compounds was evaluated. The re-adhesion of cells to the substrate (other cells or extracellular matrix) is important for cell survival and proliferation.²¹ Cells treated with non-toxic doses of Ru complexes (1/4 IC₅₀ and 1/8 IC₅₀) were detached after 24 h of incubation and re-seeded into 96-well plates. The time necessary for tumor cell adhesion depends on the tumor type, but usually occurs within 10 to 30 min, so the chosen 1 h of incubation was enough to obtain reliable control. As shown in **Figs. 4A** and **S2**, the most significant inhibition of cell adhesion was observed with **Ru3** followed by **Ru1** in the three cell lines A375, MCF-7 and MDA-MB-231, while for A2058 cells, the effect was marginal. The induced decrease in re-adhesion was concentration-dependent, particularly for A375 cells under normoxic conditions (**Fig. S2**). Hypoxic conditions made A375 cells less affected by the treatment with Ru (II) complexes, preserving

their re-adhesion properties close to the control. The low impact of Ru compounds on the adhesion and re-adhesion properties of A375 cells under hypoxic conditions suggests that oxygen-deprived conditions induce phenotypic changes in cells, making them more resistant to molecular changes induced by the studied compounds.

Furthermore, the ability of cancer cells pre-treated with Ru complexes to adhere to a monolayer of endothelial cells was assessed. This process is relevant for intravasation and extravasation, where the initial arrest and attachment of tumor cells to the vascular endothelium is a prerequisite. To distinguish cancer cells from endothelial cells, the former were fluorescently labeled. As shown in **Fig. 4B** the adherence to endothelial cells is only significantly influenced in the case of treatment of A2058 cells with **Ru1**.




Fig. 4. Cells' ability to re-adhere to plastic (A) or monolayer of endothelial cells (B), measured after 24 h incubation with $[\text{Ru}(\text{dip})_2(\text{bpy})]\text{Cl}_2$ (**Ru1**, blue), $[\text{Ru}(\text{dip})_2(\text{bpy-NitroIm})]\text{Cl}_2$ (**Ru2**, gray) and $[\text{Ru}(\text{dip})_2(\text{bpy-SC})]\text{Cl}_2$ (**Ru3**, red) under normoxic (filled bar) and hypoxic (dashed bar) conditions ($[\text{Ru}] = \frac{1}{4} \text{IC}_{50}$). Untreated cells were used as a control (100%, dashed line). * $p < 0.05$

Such an effect of Ru compounds on the adhesion properties of cancer cells, i.e., reinforcement of adhesion and inhibition of re-adhesion of cells to the plastic surface, may arise from the involvement of a different set of cell adhesion molecules (CAM) engaged in

receptor-mediated cell de-adhesion from the surface compared to the re-adhesion process. In both cases **Ru3** exhibited high activity in blocking these processes; however, its activity depends on the cell line. The obtained results confirm the existence of a clear heterogeneity between cell lines, further exacerbated by hypoxic conditions. At the molecular level, one of the possible targets for Ru complexes would be integrins that are involved in the direct cell-cell or cell-substrate (ECM) interactions responsible for adhesion. In addition, other components of focal adhesion can be involved in the detachment process. This issue is further discussed in detail below.

2.3. Impact on the migration, invasion, and transmigration of cancer cells

Cell migration is an important feature of metastatic cells and is involved in many steps of the metastasis cascade. Cell migration is a complex process that, among others, involves a subtle balance of adhesion and detachment, cytoskeleton remodeling, and the generation of protrusive force, and is strongly influenced/regulated by the extracellular matrix.²² The effect of the investigated Ru compounds on cell migration was studied using a trans-membrane migration assay (Transwell chamber).¹⁰ To evaluate the impact of Ru(II) complexes on cell migration, cells were seeded in the upper chamber, and an appropriate concentration of Ru(II) compound was added in a medium supplemented with 1% FBS. Cell movement to a lower well containing medium with the same concentration of Ru(II) compound and 20% FBS separated from the upper chamber by a microporous membrane was quantified after 16 h by counting cells stained with crystal violet in the lower chamber. The chemotactic gradient created just by the addition of serum in the lower well was enough to promote migration of A375 and MDA-MB-231 while A2058 and MCF-7 had to be starved in serum-free medium for 24 prior to the experiment. As shown in **Figs. 5, S3 and S4**, all three studied compounds

inhibited migration, however, only **Ru3** was able to suppress mobility above 50%. Hypoxic conditions tested for A375 cells had no significant effect on the inhibitory effect of Ru compounds. Another protocol involving preincubation of cells with the Ru(II) complexes for 24 h prior to seeding them in the upper chamber was applied to evaluate how changes in adhesion properties induced by Ru complexes influence cell mobility. Again, **Ru3** was also the most efficient inhibitor (**Figs. S5 and S6**). Generally, the inhibition of cell mobility was slightly stronger compared to cells treated directly in the upper chamber, which may explain the hampered detachment of cells from the plastic surface in the case of direct incubation of cells with Ru complexes on the inserts.

The invasion was evaluated using a Transwell chamber, in which a microporous membrane was pre-coated with matrigel matrix. The invasion was assessed for A375 and MDA-MB-231 cells, which were characterized by high mobility. For both cell lines, **Ru3** was the strongest inhibitor of invasion, and the observed effect was concentration dependent (**Figs. 5 and S7**). The invasion of MDA-MB-231 cells was less attenuated by all tested compounds compared to A375 cells. For a higher concentration ($1/4\text{ IC}_{50}$), all three compounds suppressed invasion by more than 50% in A375 cells, while in MDA-MB-231, only **Ru3** was so efficient. This may be explained by a much higher invasion potency of MDA-MB-231 cells.²³

Furthermore, the trans-endothelial migration through the monolayer of endothelial HMEC-1 cells was evaluated. To differentiate between cancer and endothelial cells, the former were fluorescently labeled. Treatment of cancer cells with the studied compounds led to a reduction in the total number of transmigrating cells at a level similar to that found for matrigel and again, the **Ru3** compound exhibited the strongest inhibitory activity (**Figs. 5 and**

S8). Crossing endothelial barriers is required for intra- and extravasation processes and blocking these processes can help to inhibit the spread of cancer cells.




Fig. 5 Effects of $[\text{Ru}(\text{dip})_2(\text{bpy})]\text{Cl}_2$ (Ru1, blue), $[\text{Ru}(\text{dip})_2(\text{bpy-NitroIm})]\text{Cl}_2$ (Ru2, gray) and $[\text{Ru}(\text{dip})_2(\text{bpy-SC})]\text{Cl}_2$ (Ru3, red) on migration, invasion and transmigration of **A) A375** and **B) MDA-MB-231** cells under normoxic (filled bar) and hypoxic (dashed bar) conditions. ($[\text{Ru}] = 1/8 \text{ IC}_{50}$) Untreated cells were used as control (100%, dashed line).

Mobility, invasion, and transmigration ability decreased significantly in studied cells treated with **Ru3** compared to non-treated control cells. In further studies, an attempt was made to identify molecular targets responsible for the observed effects induced in cells by Ru compounds.

2.4. Alteration of integrins accessibility

Integrins are cell surface proteins responsible for cell adhesion to the extracellular matrix (ECM) and endothelial cells. The anchoring of cells through integrins to ECM results in the transduction of signaling events that regulate many cellular processes such as cell survival, proliferation, and migration. Due to the observed changes in cell migration and adhesion properties, integrins might be the possible targets for Ru compounds. To elucidate whether the studied Ru complexes may be involved in regulating these monomeric or heterodimeric receptors, specific α and β integrin-binding assays were used to evaluate their effect on integrin translation and/or stability in MDA-MB-231 cells. In the performed study the impact of Ru complexes was evaluated by monitoring changes in their accessibility to appropriate antibodies compared to untreated cells. Initial experiments using untreated MDA-MB-231 cells identified that these cells bound more efficiently to wells coated with the following array of integrin subunits/heterodimers monoclonal antibodies: $\alpha 1$, $\alpha 2$, $\alpha 3$, $\alpha 5$, $\beta 1$, $\beta 4$, $\alpha v \beta 3$, $\alpha v \beta 5$ and $\alpha 5 \beta 1$, and only those were further analyzed. Treatment with all three studied Ru compounds resulted in a decrease in functional α integrin subunits and $\alpha v \beta 3$ heterodimer accessibility on the cell surface of the MDA-MB-231 cells (**Fig. 6A**). In the case of integrins $\beta 4$ subunit as well as $\alpha 5 \beta 1$ heterodimer a significant down-regulation of cell surface production was observed only after treatment of MDA-MB-231 cells with **Ru2** (**Fig. 6B**). On

the contrary, treatment with **Ru3** and **Ru1** led to significantly elevated availability of $\alpha\text{v}\beta 5$ heterodimer and $\beta 4$ subunit, respectively (**Fig. 6B**).

Integrin expression in various types of human cancer was shown to be correlated with tumor cell invasion and migration potency, and, among them, $\alpha\text{v}\beta 3$, $\alpha\text{v}\beta 5$, and $\alpha 5\beta 1$ are well recognized.²⁴ Inhibition of integrin functionality can affect contact with extracellular matrix components or endothelial cells (altering adhesion properties), disrupt signal transduction cascades that support migration, or both. Inhibition of $\alpha 5\beta 1$ by **Ru2** can suppress MDA-MB-231 cell migration (**Fig. 5B**) by affecting the migration machinery through signaling transduction. This type of inhibitory effect has already been reported.²⁵ It was shown that in breast cancer, $\alpha\text{V}\beta 5$ integrin is involved in cell migration through the regulation of urokinase that triggers cytoskeletal rearrangement and activation of protein kinase C.²⁶ Only **Ru3** positively affected $\alpha\text{V}\beta 5$ integrin accessibility, but the mechanism underlying the observed changes is unclear. $\alpha\text{V}\beta 3$ integrin was demonstrated to be responsible for cell motility and trans-endothelial migration by supporting hypokinetic migration (relying on adhesion to the substrate) and activating matrix-degrading MMP-2.^{22, 27} Therefore, the observed suppression of $\alpha\text{V}\beta 3$ integrin functionally by all investigated Ru compounds explains their effect on the reduction of cell mobility, invasion, and transmigration (**Fig. 5**) as well as re-adherence of cells (**Fig. 4**). It should be noted that the superior effect of **Ru3** cannot be explained solely by its impact on integrins, suggesting the involvement of other targets.




Fig 6. Protein expression/binding profile of α (A) and β (B) integrin subunits and heterodimers on MDA-MB-231 cells measured after 2h incubation with $[\text{Ru}(\text{dip})_2(\text{bpy})]\text{Cl}_2$ (**Ru1**, blue), $[\text{Ru}(\text{dip})_2(\text{bpy-NitroIm})]\text{Cl}_2$ (**Ru2**, gray) and $[\text{Ru}(\text{dip})_2(\text{bpy-SC})]\text{Cl}_2$ (**Ru3**, red) ($[\text{Ru}] = \frac{1}{4}\text{IC}_{50}$). Data are represented as the mean fold increase over untreated cells used as a control (100%, dashed line).

2.5. Ru complexes induced cell adhesion strengthening – contributions from focal adhesion assembly and cytoskeleton changes

As discussed in *Chapter 2.2*, the studied compounds greatly impacted on cell adhesion to cell culture plates (**Fig. 3**). To gain better insight into the mechanism underlying the observed effect, the average number of focal adhesions (FAs) for MDA-MB-231 cells treated with **Ru3** for 24 h was counted (**Fig. S9**). As shown in **Fig. 7**, the number of FAs was significantly higher in **Ru3**-treated cells than the non-treated control.




Fig. 7. Quantification of focal adhesions (FAs) in MDA-MB-231 cells after 24 h of treatment with $[\text{Ru}(\text{dip})_2(\text{bpy-SC})]\text{Cl}_2$ (**Ru3**), untreated cells were used as control (dashed line). The bars represent the mean number of FAs per cell of ~ 60 randomly selected adherent cells, calculated using ImageJ software. Focal adhesions were visualized by vinculin staining. * $p < 0.05$.

To gain further insight in the FAs assembly, the expression of focal adhesion components vinculin and paxillin was evaluated for MDA-MB-231 cells treated with non-toxic doses of the investigated compounds. As shown in **Figs. 8A** and **8B**, the expression of vinculin was significantly increased by **Ru3**, while the lowest impact was observed for **Ru1**. More studies are needed to check whether Ru compounds also regulate vinculin activation. It was already shown that the recruitment of the focal adhesion structural protein vinculin could increase in adhesion strength after an initial binding.^{27a} Paxillin is another major component of focal adhesion, which may exert positive or negative effects on cell migration.²⁸ Expression of paxillin increased significantly after treatment with **Ru1** and **Ru3** (**Figs. 8A** and **8C**). Since the function of paxillin is tightly regulated by phosphorylation²⁹, the amount of

phosphorylated protein was additionally measured. As shown in **Figs. 8A** and **8D**, the 24 h treatment of MDA-MB-231 cells with Ru complexes increased the efficiency of paxillin phosphorylation on Tyr118 site.




Fig. 8. A) Western blots of vinculin, paxillin, phospho-paxillin(Tyr118) and β -actin in MDA-MB-231 cells treated with Ru complexes for 24 h (representative images). B), C), D) A quantification of protein levels of focal adhesion components vinculin (B), paxillin (C) and phospho-paxillin (D) in MDA-MB-231 cells after 24 h of treatment with **[Ru(dip)₂(bpy)]Cl₂ (Ru1, blue), [Ru(dip)₂(bpy-NitroIm)]Cl₂ (Ru2, gray) and [Ru(dip)₂(bpy-SC)]Cl₂ (Ru3, red)**. Untreated cells were used as control (dashed line). The expressions of proteins were calculated with respect to β -actin. Data are represented as mean \pm SEM. *p < 0.05.

Furthermore, the morphology of MDA-MB-231 cells treated with Ru complexes was visualized by fluorescent staining of F-actin using a selective high-affinity probe ActinGreen 488 ReadyProbes (ThermoFisher Scientific). Representative images of cancer cells treated with the most active **Ru3** are presented in **Fig. S10**. However, the observed changes are rather subtle (**Fig. S10**) and did not allow one to form a definite statement regarding reorganization of F-actin filaments.

A cell elasticity study was conducted using atomic force microscopy (AFM) to obtain semiquantitative information regarding the reorganization of the cell cytoskeleton. A significant advantage of this study is that measurements were performed on living cells in a physiologically relevant environment. Details of this method were described earlier.³⁰ Briefly, it is based on indenting the cell using a delicate cantilever with a probing tip mounted at the free end. The cantilever deflection is measured as a function of sample position (**Fig. 9A**). It is converted into the relationship between the load force and indentation. Elastic properties of cells are quantified through Young's (elastic) modulus. The AFM study of the mechanical properties of MDA-MB-231 cells after treatments with the most active compound, i.e., Ru3, revealed Young's modulus increase of Ru-treated cells compared to the vehicle-treated control (**Fig. 9B**). Higher moduli values indicated larger rigidity of the cancer cells upon Ru treatments, which accounts for the decrease in cell deformability. It was suggested that the different F-actin organization might be responsible for these changes in cell elasticity.³¹ Numerous studies showed that cancer progression induced alterations in cell deformability in most cancers.³⁰ Furthermore, some studies revealed a correlation between cell deformability and their metastatic potential.³²

The observed impairment in cell migration and adhesion induced by the studied **Ru3** compound might arise from the alteration of the organization of the cancer cell cytoskeleton. The results are in line with our previous study, which revealed preferential accumulation of **Ru3** in the cytoskeleton fraction of cancer cells.¹³ The findings of the AFM elasticity study (**Fig. 9B**) are also supported by the observed increase in vinculin expression after the treatment of cells with Ru compounds (**Fig. 7D**). Vinculin-deficient cancer cells are more deformable than the corresponding wild-type cells.³³




Fig. 9 A) Illustration of the main elements that constitute an atomic force microscope (AFM). B) Elasticity of MDA-MB-231 cells measured after 24 h of treatment with **[Ru(dip)₂(bpy-SC)]Cl₂ (Ru3)**. Young's modulus is presented as a mean \pm SEM for ~ 80 randomly selected adherent cells in respect to modulus of control cells (dashed line). * $p < 0.05$.

Conclusions

Here, we report a family of Ru complexes that regulate the cell adhesion properties. On one hand, they strengthen the attachment of cells in plastic well; on the other hand, when cells are

treated with Ru complexes after their detachment, the re-adherence to plastic or endothelial monolayer is pronouncedly decreased. Adhesion formation and disassembly drive cell migration and play a crucial role in the propensity of cancer cells to invade. All studied compounds pronouncedly decreased migration, invasion, and transmigration – key metastasis processes. It is not without significance that the observed functional changes in cells are recorded for doses much lower than cytotoxic. The most potent compound was **Ru3**, which exhibited significant changes in cell adhesion and motility. It demonstrated excellent uptake by cells and was particularly cytotoxic against highly invasive MDA-MB-231 cells. The insight in the molecular bases of the observed cell functional changes revealed that the studied compounds influence the integrin functionality and expression of the focal adhesion components vinculin and paxillin, resulting in an increased number of focal adhesion contacts. Furthermore, the observed increase in cell elasticity after treatment with **Ru3** may be related to its impact on cytoskeleton. Taken together, it seems that studied Ru compounds can act simultaneously on several targets in the metastatic cascade that make them interesting candidates for their application as efficient antimetastatic agents. Applying hypoxic conditions, often encounter in solid tumors, did not change the cytotoxicity of the studied compounds in a significant manner, but their influence on cell adhesion and mobility was smaller.

We recognize that *in vitro* platforms used in the present study have many limitations in relation to *in vivo* experiments; however, they may provide clues as to potential properties of the studied compounds that may deregulate or disrupt metastatic cascade.

Experimental Section

Materials

Unless otherwise stated, the reagents were purchased from Sigma-Aldrich. All complexes [Ru(dip)₂(bpy)]Cl₂ (**Ru1**), [Ru(dip)₂(bpy-NitroIm)]Cl₂ (**Ru2**) and [Ru(dip)₂(bpy-SC)]Cl₂ (**Ru3**) were prepared according to the published procedures. Their purity and identity was confirmed by HPLC (>95% pure) and ¹H NMR together with HRMS analysis (HPLC traces and NMR spectrum are shown in Supporting Information, Table S1).^{27b, 34} The stock solutions of the Ru(II) polypyridyl complexes were prepared in DMSO.

Cell culturing and cytotoxicity assay

The *in vitro* studies were conducted using two human breast cancer cell lines and two human melanoma cell lines as well as the human non-tumor immortalized keratinocyte cell line. Estrogen receptor-positive MCF-7 cells were cultured in EMEM medium supplemented with 2 mM Glutamine, 1% Non-Essential Amino Acids (NEAA) (v/v), 10% Fetal Bovine Serum (FBS) (v/v) and 1% penicillin-streptomycin solution (100 units/mL-100 µg/mL) (v/v) at 37 °C in humidified atmosphere with 5% CO₂ (v/v). Triple-negative MDA-MB-231 cells were cultured in L15 medium supplemented with 2 mM Glutamine, 15% Fetal Bovine Serum (FBS) (v/v) and 1% penicillin-streptomycin solution (100 units/mL-100 µg/mL) (v/v) at 37 °C in humidified atmosphere. Low metastatic melanoma A375 cells were cultured in DMEM medium supplemented with 2 mM Glutamine, 15% Fetal Bovine Serum (FBS) (v/v) and 1% penicillin-streptomycin solution (100 units/mL-100 µg/mL) (v/v) at 37 °C in humidified atmosphere with 5% CO₂ (v/v). Highly metastatic melanoma A2058 cells were cultured in EMEM medium supplemented with 2 mM Glutamine, 1% Non-Essential Amino Acids (NEAA) (v/v), 10% Fetal Bovine Serum (FBS) (v/v) and 1% penicillin-streptomycin solution (100 units/mL-100µg/mL) (v/v) at 37 °C in humidified atmosphere with 5% CO₂ (v/v). Human non-cancerous immortalized keratinocytes cells HaCaT were cultured in DMEM medium supplemented with 10% Fetal Bovine Serum (FBS) (v/v) and 1% penicillin-

streptomycin solution (100 units/mL-100 μ g/mL) (v/v) at 37°C in humidified atmosphere with 5% CO₂ (v/v).

Hypoxic conditions were maintained in a humidified hypoxic chamber (Coy) filled with a gas mixture comprising 94 % N₂, 5% CO₂ and, 1% O₂. For the experiments performed in hypoxic conditions, cells were seeded under normal conditions and then moved to the hypoxic chamber for at least 24 h preincubation. Medium intended to be used in hypoxic experiments was also preincubated in the hypoxic chamber for at least 24 h.

Cell viability upon treatment with Ru(II) complexes was determined using the Alamar Blue assay. Cells were seeded into 96-well plates with the density of 3×10^4 cells per cm² in complete medium and cultured for 24 h. Subsequently, cells were incubated with various concentrations of the studied complexes for 24 h. Stock solutions of the Ru(II) complexes were prepared in DMSO. The final concentration of DMSO in cell culture was fixed at 0.1% (v/v). After 24 h of incubation, cells were washed with PBS and incubated in Alamar Blue solution for 3 h at 37 °C. Subsequently, the fluorescence was measured using a Tecan Infinite 200 microplate reader at 605 nm using 560 nm excitation light. The experiments were performed in triplicate and repeated three times. Results are presented as a mean value and standard error of the mean. IC₅₀ parameters were determined using the Hill equation (OriginPro 2018).

Cellular uptake of Ru compounds

Cellular uptake of the Ru complexes was determined using the all-tested cell line. Cells were seeded in 6-well plates with a density of 4×10^4 cells per cm² in a complete medium and cultured for 1 day. Next, cells were incubated with non-toxic concentrations of the Ru complex (either 1/8 or 1/4 of IC₅₀) for 24 h. Subsequently, the incubated cells were washed, detached by trypsin treatment, counted, and centrifuged. The supernatant was removed, and

cells were digested in concentrated nitric acid overnight at room temperature. The solutions were then diluted with Millipore water to a final nitric acid concentration of 1%. Samples were analyzed using inductively coupled plasma mass spectrometry (ICP-MS, NexION 2000C, Perkin Elmer). The results were calculated as the Ru concentration per cell. The experiments were repeated three times.

Trypsin resistance assay

The influence of the susceptibility of cells to detachment upon incubation with Ru(II) complexes was evaluated by checking their resistance to trypsin treatment. Cells were seeded into 96-well plates with the density of 3×10^4 cells per cm^2 in a complete medium and cultured for 24 h. Then, cells were incubated with various concentrations of Ru(II) complexes (either 1/8 or 1/4 of IC_{50}) for 24 h. Subsequently, the cells were washed, and 30 μL trypsin solution (0.05% for A2058 and MCF-7, 0.01% for A375 and MDA-MB-231) was added to each well for 5 min of incubation at 37 °C. The cells were then washed with PBS, and an Alamar Blue assay was performed to quantify adherent cells. The received results were normalized with appropriate wells without trypsin treatment to exclude the possible toxicity of the studied compounds and presented as a percentage of control cells. For melanoma cell lines experiments were performed under normoxic and hypoxic conditions. The experiments were carried out in triplicate, and each experiment was repeated five times to obtain the mean values and the standard error of the mean.

Re-adherence to the substrate

The effect of the studied complexes on the adhesion properties of cancer cells was also examined by evaluating the ability of the treated cells to re-adhere. Cells were seeded into 6-well plates with the density of 3×10^4 cells per cm^2 in a complete medium and cultured for 24

h. Then, the medium was removed and various concentrations of the studied Ru(II) complexes were added and incubated with the cells for 24 h. Subsequently, cells were washed and incubated with a fresh portion of PBS without Mg and Ca ions for 20 min. Then, the cells were detached with a cell dissociation solution, counted, and seeded into 96-well plates with the density of 6×10^4 cells per cm^2 . The plates were incubated for 1 h in a humidified atmosphere at 37 °C and then were washed with PBS to remove non-adherent cells. A resazurin assay was performed to quantify adherent cells. Detachment of MCF-7 cells treated with Ru3 was not possible by using the cell dissociation solution, so instead a trypsin solution (0.05%) was used. For melanoma cell lines experiments were performed under normoxic and hypoxic conditions. The experiments were carried out in triplicate and each experiment was repeated five times to calculate the mean values and the standard error of the mean.

To evaluate re-adhesion of cancer cells to the monolayer of endothelial cells, HMEC-1 cells were seeded in a 24-well plate with the density of 4×10^4 cells per cm^2 in a complete medium 2 days before the experiments. Cancer cells were seeded in 6-well plates with the density of 3×10^4 cells per cm^2 in a complete medium and cultured for 24 h. The medium was removed and various concentrations of the studied Ru(II) complexes were added and incubated with the cells for another 24 h. After incubation, cancer cells were washed and detached with a trypsin solution (0.05%). The cancer cells were labeled with CellTracker Green CMFDA Dye (Invitrogen, Thermofisher Scientific) according to the manufacturer's instructions and counted. Labeled cancer cells were added to an endothelial cell monolayer at cancer to endothelial cells ratio = 1: 1. Cells were incubated in a CO₂ incubator for 1 h in serum free medium, and then gently washed with PBS twice (to detach non adherent cells). The cells were detached by trypsin and analyzed by flow cytometry. The experiment was carried out in triplicate and repeated 5 times.

Migration, Invasion and Transmigration assays

The cell migration assay was tested using a commercial Transwell insert (8 μm pore size, Corning). Before the experiment, A2058 and MCF-7 cells were starved with a serum-free medium for 24 h. A375 and MDA-MB-231 cells were tested without prior incubation in a medium without FBS. Next, 5×10^4 (for A375 and MDA-MB-231) or 1×10^5 (for A2058 and MCF-7) cells in a serum-free medium were added to the upper chamber and a medium with 20% FBS was added to the lower chamber. The studied ruthenium complexes at various concentrations were added to both inserts and wells. After 16 h of incubation, the inserts were washed with PBS and the cells on the membrane were first fixed with 10% formalin and then stained with 0.5% crystal violet. After that, non-migrated cells were removed from the upper surface of the membrane using a cotton swab. Crystal violet was then dissolved in methanol and absorbance was measured using a Tecan Infinite 200 microplate reader at 590 nm with 700 nm as a reference wavelength. The experiments were performed in duplicate, and each experiment was repeated twice to obtain the mean values and the standard error of the mean. The results are presented as a percentage of control cells not treated with Ru compounds.

In the invasion assay, the Transwell Boyden chamber was pre-coated with matrigel (1 mg/mL for MDA-MB-231 or 2 mg/mL for A375 cells) for 2 h at 37 °C. The rest of the procedure was the same as for the migration assessment.

In the transmigration assay, firstly, 3×10^4 HMEC-1 cells in full-serum were seeded in the upper chamber and allowed to form a monolayer over 24 h. Next, endothelial cells were activated with 10 $\mu\text{g/mL}$ TNF α for 15 min. Parallel, tumor cells were seeded into 6-well plates with the density of 3×10^4 cells per cm^2 in complete medium and cultured for 24 h. Then, the medium was removed. Various concentrations of the studied Ru(II) complexes were added and incubated with the cells for 24 h. Afterward, the cells were washed, detached with trypsin, counted, and stained with CellTracker™ Green CMFDA Dye. A tumor cell

suspension was added above the endothelial monolayer with a density of 1×10^5 in a serum-free medium. Medium with 20% FBS was introduced into the lower chamber and incubated for 16 h. After this time, the inserts were washed with PBS, and non-invasive cells were removed from the upper surface of the membrane using a cotton swab, and the fluorescence was measured using a Tecan Infinite 200 microplate reader at 535 nm using 485 nm excitation light. The experiments were performed in duplicate, and each experiment was repeated twice to obtain the mean values and the standard error of the mean. Results are presented as a percentage of control cells.

For melanoma cell lines migration, invasion and transmigration experiments were performed under normoxic and hypoxic conditions.

Integrin binding assay

The influence of the complexes on the expression of specific integrins on the cell surface was assessed using an Alpha/Beta Integrin-Mediated Cell Adhesion Array Combo Kit (ECM535 Millipore). MDA-MB-231 cells were grown to confluence in 75 cm² flasks. Then, the cells were washed and detached with a cell dissociation solution. In the next step, cells were counted and the suspension was prepared with a density of 1×10^6 cells per 1 ml in L-15 medium. The suspension was divided into portions and Ru(II) compounds in DMSO were added to obtain an appropriate concentration (the DMSO concentration was kept at 0.1% v/v). 100 µL of such prepared cell suspensions was added to the integrin antibody-coated and control wells and incubated for 2 hours at 37 °C. The unbound cells were then washed off and the adherent cells were stained with CyQuant GR dye. Subsequently, the fluorescence was measured using a Tecan Infinite 200 microplate reader at 530 nm using 485 nm excitation light. The data are combined from three independent experiments. Each sample was assayed

twice. Data are represented as the mean percentage of control and the standard error of the mean.

Cell lysis and immunoblotting

Expression levels of focal adhesion components vinculin, paxillin and phospho-paxillin(Tyr118) were measured by western blot technique in MDA-MB-231 protein extracts. After 24 h of incubation with the studied Ru(II) complexes, cells were rinsed twice with PBS (4 °C) and lysed on ice with RIPA lysis buffer. Lysates were purified by centrifugation, and protein concentrations were determined by the Bradford method using bovine serum albumin as standard. Then to 30 µL of each lysate sample 10 µL of sample buffer (0.5 M TRIS, 10% glycerol, b-mercaptoethanol, 10% SDS) was added. The samples were heated at 95 °C for 5 min. The obtained protein extracts were subjected to pre-electrophoresis (60 V/25 min) and electrophoresis (170 V/50 min) on a 12.5% SDS polyacrylamide gel at room temperature using a PowerPac™ Basic Power Supply (Bio-Rad, Inc., Hercules, CA, USA). PageRuler™ Prestained Protein Ladder (Thermo Fisher Scientific) was used to determine the approximate molecular weights of resolved proteins. A wet electrotransfer was carried out for 2 h at a constant current of 200 mA to transfer the separated proteins to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Inc., Hercules, CA, USA). Furthermore, the membrane was probed with primary antibody overnight at 4°C: mouse monoclonal anti-paxillin antibody (dilution 1:250; Thermo Fisher Scientific, catalogue number AH00492); rabbit monoclonal anti-vinculin antibody (dilution 1:500; Thermo Fisher Scientific, catalogue number 42H89L44), rabbit polyclonal anti-phospho-paxillin (Tyr118) antibody (dilution 1:1000; Thermo Fisher Scientific, catalogue number 44-722G) or mouse monoclonal anti-βactin antibody (dilution 1:1000; Thermo Fisher Scientific, catalogue number AM4302), and secondary antibody for 2 h at room temperature: goat anti-mouse antibody (dilution 1:10,000;

Thermo Fisher Scientific, catalogue number G21040) for paxillin and β -actin detection or goat anti-rabbit antibody (dilution 1:10,000; Thermo Fisher Scientific, catalogue number G21234) for vinculin and phospho-paxillin detection. Reactive protein was detected using GE Healthcare Amersham™ ECL Prime Western Blotting Detection Reagent (GE Healthcare Inc., Chicago, IL, USA). Data were collected by ChemiDoc XRS+ Imaging System (Bio-Rad, Inc., Hercules, CA, USA) and analyzed with Image Lab v. Software 6.1.0 software (Bio-Rad, Inc., Hercules, CA, USA). The analysis was done using three independent biological repetitions. β -actin was used for normalization.

Fluorescence imaging

The cultured cells were gradually fixed with PFA (10 min 1% and 10 min 2%) and permeabilized for 5 min in PBS containing 0.2 % triton-X100. For focal adhesions (FAs) staining, Anti-vinculin FITC conjugated mouse monoclonal antibody (dilution 1:50; F7053 Sigma Adrich) was used and incubated for 1 h at room temperature followed by imaged with the Olympus IX83 microscope (λ_{ext} at 470 nm, λ_{em} at 525). Data represents the mean number of FAs per one cell of ~60 randomly selected adherent cells, calculated using the ImageJ software. According to the attached protocol, cytoskeletons were stained using Actin green™ 488 Ready Probes™ (Life Technologies R37110). Images were taken using an Olympus IX83 microscope (λ_{ext} at 470 nm, λ_{em} at 525).

Atomic force microscopy - elasticity measurements

To assess the relative changes in mechanical properties of MDA-MB-231 cells after Ru3 treatments, AFM experiments were carried out using XE-120 (Park System, South Korea) with a combined Olympus IX71 inverted optical microscope (Olympus, Japan). The optical microscope was used to move and align cantilevers above the cells. Measurements were

performed using commercially available silicon nitride cantilevers with a nominal spring constant of 0.03 N/m, open-angle of 36° and tip radius of 10 nm (PNP-TR-B, Nanoworld). Prior to the experiments, the spring constant of the cantilever was measured using the thermal noise calibration. MDA-MB-231 cells were seeded into 6-well plates on glass coverslips (15 mm \times 15 mm) with a density of 4×10^3 cells per cm^2 in complete medium and cultured for 24 h. This small seeding density was chosen to avoid the influence of neighboring cells on the measurements made. Then, cells were incubated with various concentrations of Ru3 (either 1/8 or 1/4 of IC_{50}) for 24 h. After incubation, cells were washed with DPBS, and the coverslip with cells was transferred to a “liquid cell” placed on an AFM scanner. The measurements were conducted in the basal cell culture medium at room temperature. An average experiment lasted no more than 2 hours to preserve the viability of the cells. Cells were indented approximately over the nuclear region of individual cells. The 25 force curves were recorded over a scan area of $25 \mu\text{m}^2$. During each experiment, 20 cells were measured for each studied condition. The experiments were repeated four times. The force curves were converted into force versus indentation curves and further analyzed. For Young’s modulus determination, the probe shape was assumed to be conical. The average values of Young’s modulus were calculated and presented as the mean value with the standard error of the mean.

Statistical analysis

For in vitro experiments, all data were expressed as the mean and standard error of the mean (SEM). For statistical analysis between the control group and the experiment groups, a one- way analysis of variance (ANOVA) was performed, and the Mann- Whitney U test was performed for statistical analysis when the data did not accord with the homogeneity of variance (Statistica 13.3). Probabilities of $p < 0.05$ were considered statistically significant. The following notification is used * $p < 0.05$.

Author information

Corresponding Authors

Olga Mazuryk - *Faculty of Chemistry, Jagiellonian University in Krakow, Gronostajowa 2, 30-387 Krakow, Poland* E-mail: olga.mazuryk@uj.edu.pl ORCID <https://orcid.org/0000-0001-6973-3614>

Malgorzata Brindell - *Faculty of Chemistry, Jagiellonian University in Krakow, Gronostajowa 2, 30-387 Krakow, Poland.* E-mail: malgorzata.brindell@uj.edu.pl ORCID <https://orcid.org/0000-0002-9827-4661>

Authors

Ilona Gurgul - *Faculty of Chemistry, Jagiellonian University in Krakow, Gronostajowa 2, 30-387 Krakow, Poland;* ORCID <https://orcid.org/0000-0003-0462-6492>

Ewelina Janczy-Cempa - *Faculty of Chemistry, Jagiellonian University in Krakow, Gronostajowa 2, 30-387 Krakow, Poland;* ORCID <https://orcid.org/0000-0001-5787-441X>

Malgorzata Lekka - *Department of Biophysical Microstructures, Institute of Nuclear Physics, Polish Academy of Sciences, PL-31342 Krakow, Poland;* ORCID <https://orcid.org/0000-0003-0844-8662>

Michał Łomzik - *Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, ul. Tamka 12, 91-403 Łódź, Poland ;* ORCID <https://orcid.org/0000-0003-4847-3520>

Franck Suzenet - *Institute of Organic and Analytical Chemistry, University of Orléans, UMR-CNRS 7311, rue de Chartres, BP 6759, 45067 Orléans Cedex 2, France;* ORCID <https://orcid.org/0000-0003-1394-1603>

Philippe C. Gros - *Université de Lorraine, CNRS, L2CM, F-54000 Nancy, France ;* ORCID <https://orcid.org/0000-0003-4905-1581>

Author Contributions

I.G. and E. J.-C. contributed equally to this work.

All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

Acknowledgments

This research was funded by the National Science Center in Poland for the OPUS Project no. 2016/21/B/NZ7/01081. I. G. acknowledges the support from InterDokMed project no. POWR.03.02.00-00-013/16. F.S. thanks Ms. Sophie FRONT from the ICOA's organic synthesis platform for the furniture of Ru₂ ligand, the synthetic work was supported by la Ligue contre le Cancer (comité du Loiret et des Deux-Sèvres), the projects CHemBio (FEDER-FSE 2014-2020-EX003677), Techsab (FEDER-FSE 2014-2020-EX011313), the RTR Motivhealth (2019-00131403) and the Labex programs SYNORG (ANR-11-LABX-0029) and IRON (ANR-11-LABX-0018-01) for their financial support of ICOA, UMR 7311, University of Orléans, CNRS.

Associated content

Supporting Information is available

Purity confirmation (Table S1), trypsin resistance assay (Fig. S1), re-adhesion assay (Fig. S2), migration, invasion, and transmigration assays (Figs. S3-S6), Molecular Formula Strings.

Abbreviations

AFM, atomic force microscopy; bpy, 2,2'-bipyridyne; bpy-NitroIm, 4-[3-(2-nitro-1H-imidazol-1-yl)propyl]; bpy-SC, 5-(4-{4'-methyl-[2,2'-bipyridine]-4-yl}but-1-yn-1-yl)pyridine-2-carbaldehyde semicarbazone; CAM, cell adhesion molecules; dip, 4,7-diphenyl-1,10-phenanthroline; DMEM, Dulbecco's Modified Eagle Medium; ECM, extracellular matrix; EMEM, Eagle's minimum essential medium; ER, estrogen receptor; Fac, focal adhesion

contacts; FBS, fetal bovine serum; HER2, human epidermal growth factor receptor; ICP-MS, inductively coupled plasma mass spectrometry; LDM, low-dose metronomic chemotherapy; MTD, maximum tolerated doses; NEAA, Non-Essential Amino Acids; PFA, paraformaldehyde; PR, progesterone receptor; PVDF, polyvinylidene difluoride; SEM, standard error of the mean

References

1. (a) Chabner, B. A., Does chemotherapy induce metastases? *Oncologist* **2018**, (23), 273-274. 10.1634/theoncologist.2017-0648; (b) Karagiannis, G. S.; Condeelis, J. S.; Oktay, M. H., Chemotherapy-induced metastasis: Molecular mechanisms, clinical manifestations, therapeutic interventions. *Cancer Res.* **2019**, 79, 4567-4576. 10.1158/0008-5472.CAN-19-1147; (c) D'Alterio, C.; Scala, S.; Sozzi, G.; Roz, L.; Bertolini, G., Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. *Semin. Cancer Biol.* **2020**, 60, 351-361. doi.org/10.1016/j.semcancer.2019.08.019; (d) Jiang, M.-J.; Gu, D.-N.; Dai, J.-J.; Huang, Q.; Tian, L., Dark side of cytotoxic therapy: Chemoradiation-induced cell death and tumor repopulation. *Trends Cancer* **2020**, 6, 419-431. doi.org/10.1016/j.trecan.2020.01.018; (e) Martin, O. A.; Anderson, R. L.; Narayan, K.; MacManus, M. P., Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? *Nat. Rev. Clin. Oncol.* **2017**, 14, 32-44. 10.1038/nrclinonc.2016.128
2. Karagiannis, G. S.; Pastoriza, J. M.; Wang, Y.; Harney, A. S.; Entenberg, D.; Pignatelli, J.; Sharma, V. P.; Xue, E. A.; Cheng, E.; D'Alfonso, T. M.; Jones, J. G.; Anampa, J.; Rohan, t. E.; Sparano, J. A.; Condeelis, J. S.; Oktay, M. H., Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. *Sci. Transl. Med.* **2017**, 9, eaan0026. 10.1126/scitranslmed.aan0026
3. Cabrera-Galeana, P.; Munoz-Montano, W.; Lara-Medina, F.; Alvarado-Miranda, A.; Perez-Sanchez, V.; Villarreal-Garza, C.; Quintero, R. M.; Porras-Reyes, F.; Bargallo-Rocha, E.; Del Carmen, I.; Mohar, A.; Arrieta, O., Ki67 changes identify worse outcomes in residual breast cancer tumors after neoadjuvant chemotherapy. *Oncologist* **2018**, 23, 670-678. 10.1634/theoncologist.2017-0396
4. Cortazar, P.; Zhang, L.; Untch, M.; Mehta, K.; Costantino, J. P.; Wolmark, N.; Bonnefoi, H.; Cameron, D.; Gianni, L.; Valagussa, P.; Swain, S. M.; Prowell, T.; Loibl, S.; Wickerham, D. L.; Bogaerts, J.; Baselga, J.; Perou, C.; Blumenthal, G.; Blohmer, J.; Mamounas, E. P.; Bergh, J.; Semiglazov, V.; Justice, R.; Eidtmann, H.; Paik, S.; Piccart, M.; Sridhara, R.; Fasching, P. A.; Slaets, L.; Tang, S.; Gerber, B.; Geyer Jr, C. E.; Pazdur, R.; Ditsch, N.; Rastogi, P.; Eiermann, W.; von Minckwitz, G., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* **2014**, 384, 164-172. 10.1016/S0140-6736(13)62422-8
5. Wang, Q.; Jiang, J.; Ying, G.; Xie, X.-Q.; Zhang, X.; Xu, W.; Zhang, X.; Song, E.; Bu, H.; Ping, Y.-F.; Yao, X.-H.; Wang, B.; Xu, S.; Yan, Z.-X.; Tai, Y.; Hu, B.; Qi, X.; Wang, Y.-

- X.; He, Z.-C.; Wang, Y.; Wang, J. M.; Cui, Y.-H.; Chen, F.; Meng, K.; Wang, Z.; Bian, X.-W., Tamoxifen enhances stemness and promotes metastasis of ER α 36+ breast cancer by upregulating ALDH1A1 in cancer cells. *Cell Res.* **2018**, 1-23. 10.1038/cr.2018.15
6. Steeg, P. S.; Anderson, R. L.; Bar-Eli, M.; Chambers, A. F.; Eccles, S. A.; Hunter, K.; Itoh, K.; Kang, Y.; Matrisian, L. M.; Sleeman, J. P.; Theodorescu, D.; Thompson, E. W.; Welch, D. R., An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. *Clin. Cancer Res.* **2009**, *15*, 4529. 0.1158/1078-0432.CCR-09-1363
 7. Lien, K.; Georgsdottir, S.; Sivanathan, L.; Chan, K.; Emmenegger, U., Low-dose metronomic chemotherapy: A systematic literature analysis. *Eur. J. Cancer* **2013**, *49*, 3387-3395. dx.doi.org/10.1016/j.ejca.2013.06.038
 8. (a) Bergamo, A.; Sava, G., Linking the future of anticancer metal-complexes to the therapy of tumour metastases. *Chem. Soc. Rev.* **2015**, *44*, 8818-8835. <https://doi.org/10.1039/c5cs00134j>; (b) Alessio, E.; Messori, L., NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry. *Molecules* **2019**, *24*, 1995. <https://doi.org/10.3390/molecules24101995>; (c) Alessio, E., Thirty years of the drug candidate NAMI-A and the myths in the field of ruthenium anticancer compounds. *Eur. J. Inorg. Chem.* **2017**, *2017*, 1549–1560. <https://doi.org/10.1002/ejic.201600986>
 9. Rausch, M.; Dyson, P. J.; Nowak-Sliwinska, P., Recent considerations in the application of RAPTA-C for cancer treatment and perspectives for its combination with immunotherapies. *Adv. Therap.* **2019**, *2*, 1900042. 10.1002/adtp.201900042
 10. Brindell, M.; Gurgul, I.; Janczy-Cempa, E.; Gajda-Morszewski, P.; Mazuryk, O., Moving Ru polypyridyl complexes beyond cytotoxic activity towards metastasis inhibition. *J. Inorg. Biochem.* **2022**, *226*, 111652. doi.org/10.1016/j.jinorgbio.2021.111652
 11. Gurgul, I.; Mazuryk, O.; Łomzik, M.; Gros, P. C.; Rutkowska-Zbik, D.; Brindell, M., Unexplored features of Ru(II) polypyridyl complexes – towards combined cytotoxic and antimetastatic activity. *Metallomics* **2020**, *12*, 784--793. 10.1039/d0mt00019a
 12. Mazuryk, O.; Suzenet, F.; Kieda, C.; Brindell, M., The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells. *Metallomics* **2015**, *7*, 553-556. doi.org/10.1039/C5MT00037H
 13. Gajda-Morszewski, P.; Gurgul, I.; Janczy-Cempa, E.; Mazuryk, O.; Łomzik, M.; Brindell, M., Inhibition of matrix metalloproteinases and cancer cell detachment by Ru(II) polypyridyl complexes containing 4,7-diphenyl-1,10-phenanthroline ligands-new candidates for antimetastatic agents. *Pharmaceutics* **2021**, *14*, 1014. doi.org/10.3390/ph14101014
 14. (a) Chavez, K. J.; Garimella, S. V.; Lipkowitz, S., Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. *Breast Dis.* **2010**, *32*, 35-48. 10.3233/BD-2010-0307; (b) Holiday, D. L.; Speirs, V., Choosing the right cell line for breast cancer research. *Breast Cancer Res.* **2011**, *13*, 215. doi.org/10.1186/bcr2889
 15. Brandes, L. J.; Hermonat, M. W., Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol. *Cancer Res.* **1983**, *43*, 2831-2835. 0008-5472/83/0043-0000\$02.00

16. (a) Jenei, V.; Sherwood, V.; Howlin, J.; Linnskog, R.; Säfholm, A.; Axelsson, L.; Andersson, T., A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion *Proc. Natl. Acad. Sci.* **2009**, *106*, 19473-19478. 10.1073/pnas.0909409106; (b) Jeffrey Wu, Y.; Pagel, M. A.; Muldoon, L. L.; Fu, R.; Neuwelt, E. A., High α_v integrin level of cancer cells is associated with development of brain metastasis in athymic rats *Anticancer Res.* **2017**, *37*, 4029-4040. 10.21873/anticancer.11788
17. (a) Kim, H.-Y.; Lee, H.; Kim, S.-H.; Jin, H.; Bae, J.; Choi, H.-K., Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. *Sci. Rep.* **2017**, *7*, no. 8864. 10.1038/s41598-017-08433-9; (b) Merighi, S.; Varani, K.; Gessi, S.; Cattabriga, K.; Iannotta, V.; Ulouglu, C.; Leung, E.; Borea, P. A., Pharmacological and biochemical characterization of adenosinereceptors in the human malignant melanoma A375 cell line. *Br. J. Pharmacol.* **2001**, *134*, 1215-1226. 10.1038/sj.bjp.0704352
18. (a) Rankin, B. E.; Nam, J.-M.; Giaccia, A. J., Hypoxia: signaling the metastatic cascade. *Trends Cancer* **2016**, *2*, 295-304. 10.1016/j.trecan.2016.05.006; (b) Rankin, E. B.; Giaccia, A. J., Hypoxic control of metastasis *Science* **2016**, *352*, 175-180. 10.1126/science.aaf4405
19. Lee, J. O.; Kang, M. J.; Byun, W. S.; Kim, S. A.; Seo, I. H.; Han, J. A.; Moon, J. W.; Kim, J. H.; Kim, S. J.; Lee, E. J.; Park, S. H.; Kim, H. S., Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. *Breast Cancer Res.* **2019**, *21*, 115. doi.org/10.1186/s13058-019-1204-2
20. Brindell, M.; Gurgul, I.; Janczy-Cempa, E.; Gajda-Morszewski, P.; Mazuryk, O., Moving Ru polypyridyl complexes beyond cytotoxic activity towards metastasis inhibition. *J. Inorg. Biochem.* **2021**. doi.org/10.1016/j.jinorgbio.2021.111652
21. Heidi Harjunpää, M. L. A., Carla Guenther and Susanna C. Fagerholm, Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. *Frontiers Immunol.* **2019**, *10*, no. 1078. 10.3389/fimmu.2019.01078
22. Friedl, P.; Brocker, E.-B., The biology of cell locomotion within three-dimensional extracellular matrix. *Cell. Mol. Life Sci.* **2000**, *57*, 41-64. 10.1007/s000180050498
23. Mierke, C. T.; Benjamin, F.; Fellner, M.; Herrmann, M.; Fabry, B., Integrin $\alpha_5\beta_1$ facilitates cancer cell invasion through enhanced contractile forces. *J. Cell Sci.* **2011**, *124*, 369-383. doi:10.1242/jcs.071985
24. Jin, H.; Varner, J., Integrins: roles in cancer development and as treatment targets. *Br. J. Cancer* **2004**, *90*, 561 – 565. 10.1038/sj.bjc.6601576
25. Kim, S.; Harris, M.; Varner, J. A., Regulation of integrin $\alpha_v\beta_3$ -mediated endothelial cell migration and angiogenesis by integrin $\alpha_5\beta_1$ and protein kinase A. *J. Biol. Chem.* **2000**, *275*, 33920–33928. 10.1074/jbc.M003668200
26. Carriero, M. V.; Del Vecchio, S.; Capozzoli, M.; Franco, P.; Fontana, L., Urokinase receptor interacts with $\alpha_v\beta_5$ vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. *Cancer Res.* **1999**, *59*, 5307-5314.
27. (a) Galbraith, C. G.; Yamada, K. M.; Sheetz, M. P., The relationship between force and focal complex development. *J. Cell Biol.* **2002**, *159*, 695–705. 10.1083/jcb.200204153; (b) Mazuryk, O.; Maciuszek, M.; Stochel, G.; Suzenet, F.; Brindell, M., 2-Nitroimidazole-

- ruthenium polypyridyl complex as a new conjugate for cancer treatment and visualization. *J. Inorg. Biochem.* **2014**, *134*, 83-91. doi:10.1016/J.JINORGBIO.2014.02.001
28. German, A. E.; Mammoto, T.; Jiang, E.; Ingber, D. E.; Mammoto, A., Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. *J. Cell Sci.* **2014**, *127*, 1672-1683. 10.1242/jcs.132316
 29. López-Colomé, A. M.; Lee-Rivera, I.; Benavides-Hidalgo, R.; López, E., Paxillin: a crossroad in pathological cell migration. *J. Hematol. Oncol.* **2017**, *10*, 50. 10.1186/s13045-017-0418
 30. Kubiak, A.; Zieliński, T.; Pabijan, J.; Lekka, M., Nanomechanics in monitoring the effectiveness of drugs targeting the cancer cell cytoskeleton. *Int. J. Mol. Sci.* **2020**, *21*, 8786. doi:10.3390/ijms21228786
 31. Corbin, E. A.; Kong, F.; Lim, C. T.; King, W. P.; Bashir, R., Biophysical properties of human breast cancer cells measured using silicon MEMS resonators and atomic force microscopy. *Lab Chip* **2015**, *15*, 839–847. doi.org/10.1039/C4LC01179A
 32. Xu, W.; Mezencev, R.; Kim, B.; Wang, L.; McDonald, J.; Sulchek, T., Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. *PLoS One* **2012**, *7*, e46609. doi.org/10.1371/journal.pone.0046609
 33. Goldmann, W. H.; Ezzell, R. M., Viscoelasticity in wild-type and vinculin-deficient (5.51) mouse F9 embryonic carcinoma cells examined by atomic force microscopy and rheology. *Exp. Cell Res.* **1996**, *226*, 234–237. doi.org/10.1006/excr.1996.0223
 34. Łomzik, M.; Mazuryk, O.; Rutkowska-Zbik, D.; Stochel, G.; Gros, P. C.; Brindell, M., New ruthenium compounds bearing semicarbazone 2-formylpyridine moiety: Playing with auxiliary ligands for tuning the mechanism of biological activity. *J. Inorg. Biochem.* **2017**, *175*, 80-91. doi:10.1016/J.JINORGBIO.2017.07.006

For Table of Contents Only

